Ian Elliott Krop MD PhD

Breast Cancer, Hematologic Oncology

Associate Cancer Director for Clinical Research and Professor of Medicine, Yale Cancer Center

35 Park StreetSmilow Cancer Hospital at Yale-New HavenNew Haven, CT 06511

Dr. Krop is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Krop's full profile Already have an account?

Summary

Ian Krop, MD, PhD is the Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research at the Yale Cancer Center. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).

Dr. Krop received his undergraduate, medical and PhD degrees from Johns Hopkins University. He subsequently completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in hematology and medical oncology at Dana-Farber.

Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan

Education & Training

Johns Hopkins University School of MedicinePhD, 1996
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
Johns Hopkins University School of MedicineResidency, 1996 - 1999
Johns Hopkins University School of MedicineClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2023 - Present
CT State Medical License 2022 - 2027
MA State Medical License 2002 - 2023
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2014, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2017
CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2017

Publications & Presentations

PubMed

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Paolo Tarantino, Tianyu Li, Esther Ritah Ogayo, Tasnim Rahman, Molly K DiLullo
JAMA Oncology. 2026-08-01
Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.
Thomas Grinda, Hillary M Heiling, Nabihah Tayob, Karen L Smith, Raechel Davis
Breast. 2026-07-20
Minimal Residual Disease via circulating tumor DNA Predicts Exceptional Response in HER2-Positive Metastatic Breast Cancer.
Stefania Morganti, Catherine Song, Ningxuan Zhou, Katherine Santos, Pia Jain
Medrxiv. 2026-07-13

Press Mentions

Yale Cancer Center Names Deputy Director, Section ChiefJune 16th, 2026
Dr. Ian Krop Named Section Chief of Medical Oncology and Hematology and Deputy Director for Clinical Affairs for Yale Cancer Center and Smilow Cancer HospitalJune 15th, 2026
Triomics Implements AI Cancer Clinical-Trial Screening to Improve Access in ConnecticutNovember 18th, 2025